Bladder health after menopause: what clinicians should know

Obstetrics & Gynaecology · Urology

Menopause is accompanied by hormonal changes that can affect the genital and urinary tracts, contributing to lower urinary tract symptoms and urinary incontinence (UI). These manifestations are collectively associated with genitourinary syndrome of menopause (GSM), which is primarily attributed to oestrogen deficiency. Vaginal dryness, irritation, dyspareunia and vulvar atrophy may occur alongside urinary urgency, frequency, nocturia, dysuria and recurrent urinary tract infections (UTIs). Stress and urgency urinary incontinence may also develop or worsen. As these symptoms can progressively impair quality of life, proactive assessment and timely management are important components of postmenopausal care.Menopause-related urinary changesOestrogen deficiency contributes to thinning, reduced elasticity and increased fragility of the vaginal epithelium, with reduced lubrication and greater susceptibility to irritation and trauma. Atrophic changes involving the urethra and bladder trigone may also contribute to urinary symptoms. UI may occur as stress urinary incontinence (SUI), urgency urinary incontinence (UUI) or mixed urinary incontinence (MUI)The distribution of UI changes with advancing age and time since menopause. SUI is more frequently observed during the premenopausal and early postmenopausal years, whereas UUI and MUI become increasingly prevalent with ageAmong women aged 40-59 years, SUI is generally more common; however, urgency and mixed symptoms become more prominent after 60 years. MUI associated with detrusor overactivity has been identified as the predominant pattern in women older than 66 years. Although a weak association has been observed between menopause duration and UI symptoms, chronological age and other risk factors appear to have a greater influenceFactors influencing bladder healthSeveral factors may contribute to the development, persistence or severity of urinary symptoms after menopause.Body mass index and obesity: UI prevalence and severity increase with higher body mass index (BMI). Compared with women with normal BMI, an increased risk has been reported among those who are overweight and those with obesity. Weight management has therefore been associated with a lower risk and severity of UI in later lifeObstetric history: Previous pregnancy-related UI has been identified as an important predictor of incontinence later in life. During pregnancy, UI prevalence increases with gestational age, with SUI accounting for approximately 48-63% of cases. Higher parity, advanced maternal age, elevated BMI, previous vaginal delivery and pre-existing UI have been identified as risk factors. Childbirth-related injuries and inadequate pelvic floor muscle recovery may also contribute to subsequent symptomsNocturnal symptoms: Daytime leakage is generally reported more frequently than nocturnal episodes; however, nocturia and nocturnal incontinence become increasingly prominent with advancing menopausal stage. Nocturia has been reported in approximately 25% of early postmenopausal women. Greater symptom burden, particularly two or more nighttime voids, has been associated with urgency and sleep disturbancesMedication use: Urinary symptoms may be exacerbated by systemic oestrogen therapy, alpha-adrenergic blockers, certain antihistamines, beta-receptor agonists and angiotensin II receptor blockers (ARBs). Diuretics, calcium channel blockers and central nervous system depressants may also contribute. Systemic oestrogen has been associated with increased UI risk, whereas local vaginal oestrogen has not demonstrated the same associationSexual health and coital incontinence: Urine leakage during sexual intercourse, or coital incontinence, is frequently associated with SUI, followed by MUI and, less commonly, urgency incontinence. Depression, symptomatic pelvic organ prolapse, higher BMI, obesity, frequent sexual activity and greater menopausal symptom burden have been identified as contributing factors. Reduced maximal urethral closure pressure may also indicate intrinsic sphincter deficiency. Greater sexual quality-of-life impairment has been reported among women with mixed symptomsManagement approachesTreatment should be guided by the incontinence subtype, severity of GSM symptoms and individual clinical circumstances.Management approachClinical considerationsPelvic floor muscle training (PFMT)Kegel exercises are recommended as an initial intervention. Improvements in stress and urgency incontinence, leakage frequency and pelvic floor support have been reported.Vaginal oestrogenLow-dose local preparations, including estradiol tablets, creams and vaginal rings, may improve vaginal dryness, dyspareunia, atrophy, urgency, frequency, nocturia and UI.Combination therapyPFMT combined with vaginal estriol has demonstrated better outcomes than estriol alone in women with atrophic vulvovaginitis. Additional benefits have also been reported when Kegel exercises are combined with pharmacological treatment for overactive bladder and MUI.Surgical and procedural treatmentMidurethral slings, autologous pubovaginal slings, retropubic colposuspension and urethral bulking may be considered for selected cases of SUI.For refractory UUI, intravesical OnabotulinumtoxinA, sacral neuromodulation and percutaneous tibial nerve stimulation may be considered. However, treatment-related risks should be assessed. Urinary retention and UTIs may occur following OnabotulinumtoxinA, while implant-site pain, infection and lead migration may complicate sacral neuromodulation. Procedure selection should therefore be guided by comorbidities, previous surgery, tissue quality, treatment preferences and anticipated risks. Shared decision-making is essential.ConclusionBladder health after menopause is influenced by oestrogen deficiency, ageing, obesity, obstetric history and medication exposure. Urinary symptoms, including incontinence, urgency, frequency and nocturia, should not be overlooked as inevitable consequences of ageing. Through proactive assessment, appropriate pelvic floor rehabilitation, local vaginal oestrogen and individualised procedural interventions, symptom burden and quality-of-life impairment may be reduced.[1][2]Reference(s):1. Serbanescu L, Mirea S, Ionescu P, et al. Involuntary Urine Loss in Menopause-A Narrative Review. J Clin Med. 2025;14(21):7664. Published 2025 Oct 29. doi:10.3390/jcm14217664. https://pmc.ncbi.nlm.nih.gov/articles/PMC12610368/2. Allafi AH, Al-Johani AS, Babukur RM, et al. The Link Between Menopause and Urinary Incontinence: A Systematic Review. Cureus. 2024;16(10):e71260. Published 2024 Oct 11. doi:10.7759/cureus.71260. https://www.cureus.com/articles/303319-the-link-between-menopause-and-urinary-incontinence-a-systematic-review#!/